FILING ANALYSIS · FRIDAY, NOVEMBER 13
OptimizeRx Corp OPRX — 8-K: Results of Operations and Financial Condition
neutral
OptimizeRx Corp reported Q3 revenue of $21.6 million, a 17% decrease from Q3 2025, but exceeded consensus expectations with adjusted EBITDA of $6.3 million and updated 2026 revenue guidance to $87-$93 million. The company's debt repayment and cost management initiatives have improved margins, but the revenue decline and revised guidance may impact investor sentiment.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →